Literature DB >> 23584345

A review of the symptomatic management of malignant gliomas in adults.

Umang Shah1, Tara Morrison.   

Abstract

Malignant brain tumors are aggressive tumors with a very poor prognosis. Survival is on average 12 to 18 months. Patients with malignant gliomas are subject to multiple medical problems that can significantly impact their overall survival and quality of life, including seizures, cerebral edema, venous thromboembolism, cognitive and psychiatric disorders, and side effects of chemotherapy, such as nausea, vomiting, myelosuppression, constipation, and diarrhea. This article examines the evidence for managing many of these issues to reduce symptoms and improve quality of life.

Entities:  

Mesh:

Year:  2013        PMID: 23584345     DOI: 10.6004/jnccn.2013.0057

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  12 in total

1.  MicroRNA miR-1249 downregulates adenomatous polyposis coli 2 expression and promotes glioma cells proliferation.

Authors:  Baojun Fang; Guoliang Li; Chongfu Xu; Yuzuo Hui; Gang Li
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

2.  Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.

Authors:  Xing-Qi Li; Zhi-Gang Ouyang; Sheng-Hua Zhang; Hong Liu; Yue Shang; Yi Li; Yong-Su Zhen
Journal:  J Neurooncol       Date:  2014-05-20       Impact factor: 4.130

Review 3.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

4.  Seizures in patients with primary brain tumors: what is their psychosocial impact?

Authors:  John Y Shin; Sani H Kizilbash; Steven I Robinson; Joon H Uhm; Julie E Hammack; Daniel H Lachance; Jan C Buckner; Aminah Jatoi
Journal:  J Neurooncol       Date:  2016-03-15       Impact factor: 4.130

5.  Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.

Authors:  Allicia C Girvan; Gebra C Carter; Li Li; Anna Kaltenboeck; Jasmina Ivanova; Maria Koh; Jessi Stevens; Eleanor Hayes-Larson; Michael M Lahn
Journal:  Drugs Context       Date:  2015-03-10

6.  Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.

Authors:  Liang Cao; Dingding Qu; Huan Wang; Sha Zhang; Chenming Jia; Zixuan Shi; Zongren Wang; Jian Zhang; Jing Ma
Journal:  Int J Mol Sci       Date:  2016-11-18       Impact factor: 5.923

7.  Upregulation of miR-1825 inhibits the progression of glioblastoma by suppressing CDK14 though Wnt/β-catenin signaling pathway.

Authors:  Fengqin Lu; Chunhong Li; Yuping Sun; Ting Jia; Na Li; Haiyan Li
Journal:  World J Surg Oncol       Date:  2020-06-30       Impact factor: 2.754

8.  Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules.

Authors:  Tingzhun Zhu; Xiaoming Li; Lihan Luo; Xiaogang Wang; Zhiqing Li; Peng Xie; Xu Gao; Zhenquan Song; Jingyuan Su; Guobiao Liang
Journal:  J Transl Med       Date:  2015-11-12       Impact factor: 5.531

9.  The impact of dietary isoflavonoids on malignant brain tumors.

Authors:  Tina Sehm; Zheng Fan; Ruth Weiss; Marc Schwarz; Tobias Engelhorn; Nirjhar Hore; Arnd Doerfler; Michael Buchfelder; Iiker Y Eyüpoglu; Nic E Savaskan
Journal:  Cancer Med       Date:  2014-06-04       Impact factor: 4.452

Review 10.  End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective.

Authors:  Giuseppe Roberto Giammalva; Domenico Gerardo Iacopino; Giorgio Azzarello; Claudia Gaggiotti; Francesca Graziano; Carlo Gulì; Maria Angela Pino; Rosario Maugeri
Journal:  Brain Sci       Date:  2018-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.